Jay Dinerman is a Cardiology physician affiliated with U.S. Space and Rocket Center. OpenAlex indexes 43 publications with 4,769 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
930 Franklin St SE
Huntsville, AL 358014312
Telephone
256-539-4080Registry record last updated 1 Apr 2011.
Clinical trials
- Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
Sponsor: Heart Center Research, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20257 payments
- Boston Scientific CorporationProgram year20258 payments
- Biosense Webster, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.2%Antiarrhythmic26.9%Flecainide Acetate60%Amiodarone Hcl24%Propafenone Hcl16%Part D<11 patientsBeta blocker21.9%Carvedilol33%Metoprolol Succinate33%Sotalol26%Metoprolol Tartrate8%Part D<11 patients+ 6 more classes in this area
Blood & clotting
24.6%Factor Xa inhibitor23.1%Eliquis87%Xarelto13%Part D<11 patientsDirect thrombin inhibitors1.5%Pradaxa100%Part D<11 patientsNervous system
8.2%Opioid Agonist8.2%Oxycodone-Acetaminophen100%Part D≥66 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System
Journal of the American College of Cardiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”